Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs

References

1. 1.↵
   1. Bivas-Benita M.,
   2. Zwier R. I.,
   3. Junginger H. E.,
   4. Borchard G.

   Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 2005, 61 (3), 214–218.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Smyth H. D.,
   2. Hickey A. J.

   Carriers in drug powder delivery: implications for inhalation system design. Am. J. Drug Deliv. 2005, 3 (2), 117–132.

   OpenUrl
3. 3.↵
   1. Jaspart S.,
   2. Bertholet P.,
   3. Delattre L.,
   4. Evrard B.

   Study of Solid Lipid Microparticles as Sustained Release Delivery System for Pulmonary Administration. Presented at the 15th International Symposium on Microencapsulation, Parma, Italy, 2005, pp 241–242.
4. 4.↵
   1. Li X.,
   2. Jasti B. R.

   1. Wamsley A.

   Ligand-Based Targeting Approaches to Drug Delivery. In Design of Controlled Release Drug Delivery Systems; Li X., Jasti B. R. Eds. The McGraw-Hill Companies, Inc.: New York, 2006; pp 377–378.
5. 5.↵
   1. Smyth H.,
   2. Saleem I.,
   3. Donovan M.

   Emerging carriers for pulmonary drug delivery. AAPS Newsmagazine 2006, August, 12–15.
6. 6.↵
   1. Li X.,
   2. Jasti B. R.

   1. Kokate K.,
   2. Marasanapalle V. O.,
   3. Jasti B. R.,
   4. Li X.

   Physiological and Biochemical Barriers to Drug Delivery. In Design of Controlled Release Drug Delivery Systems; Li X., Jasti B. R. Eds.; The McGraw-Hill Companies, Inc.: New York, 2006; pp 63–64.
7. 7.↵
   1. Tong H. H. Y.,
   2. Chow A. H. L.

   Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing. KONA 2006, 24, 27–40.

   OpenUrl
8. 8.↵
   1. Agu R. U.,
   2. Ugwoke M. I.,
   3. Armand M.,
   4. Kinget R.,
   5. Verbeke N.

   The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2001, 2 (4), 198–209.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Torchilin V. P.

   1. Labiris N. R.,
   2. Bosco A. P.,
   3. Dolovich M. B.

   Aerosols as Drug Carriers. In Nanoparticulates as Drug Carriers; Torchilin V. P. Ed.; Imperial College Press: London, 2006; pp 367–395.
10. 10.↵
    1. Folkesson H. G.,
    2. Matthey M. A.,
    3. Westrom B. R.,
    4. Kim K. J.,
    5. Karlsson B. W.,
    6. Hastings R. H.

    Alveolar epithelial clearance of protein. Appl. Physiol. 1996, 80 (5), 1431–1445.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Sélam J. L.

    Inhaled insulin: promises and concerns. J. Diabetes Sci. Technol. 2008, 2 (2), 311–315.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    ACGIH. Threshold Limit Values and Biological Exposure Indices; ACGIH: Cincinnati, OH, 1997.
13. 13.↵
    1. Cryan S. A.

    Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 2005, 7 (1), E20–E41.

    OpenUrlPubMed
14. 14.↵
    1. Li X.,
    2. Jasti B. R.

    1. Mueller-Walz R.

    Device Controlled Delivery of Powders. In Design of Controlled Release Drug Delivery Systems; Li X., Jasti B. R. Eds.; The McGraw-Hill Companies, Inc.: New York, 2006; pp 231–268.
15. 15.↵
    1. Telko M. J.,
    2. Hickey A. J.

    Dry powder inhaler formulation. Respiratory Care 2005, 50 (9), 1209–1227.

    OpenUrlPubMed
16. 16.↵
    1. Wetterlin K.

    Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res. 1998, 5 (8), 506–508.

    OpenUrl
17. 17.↵
    1. Prime D.,
    2. Atkins P. J.,
    3. Slater A.,
    4. Sumby B.

    Review of dry powder inhalers. Adv. Drug Del. Rev. 1997, 26 (1), 51–58.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Newman S. P.

    Principles of metered-dose inhaler design. Respiratory Care 2005, 50 (9), 1177–1190.

    OpenUrlPubMed
19. 19.↵
    1. Smyth H. D.

    The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Deliv. Rev. 2003, 55 (7), 807–828.

    OpenUrlPubMed
20. 20.↵
    1. Noakes T.

    Medical aerosol propellants. J. Fluorine Chem. 2002, 118 (1–2), 35–45.

    OpenUrl
21. 21.↵
    1. Ganderton D.,
    2. Jones T.

    1. Hallworth G. W.

    The Formulation and Evaluation of Pressurised Metered Dose Inhalers. In Drug Delivery to the Respiratory Tract; Ganderton D., Jones T. Eds.; Ellis Horwood: Chichester, U.K., 1987; pp 87–118.
22. 22.↵
    1. Lenney J.,
    2. Innes J. A.,
    3. Crompton G. K.

    Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir. Med. 2000, 94 (5), 496–500.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.
    1. Newman S. P.,
    2. Weisz A. W.,
    3. Talaee N.,
    4. Clarke S. W.

    Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991, 46 (10), 712–716.

    OpenUrlAbstract/FREE Full Text
24. 24.
    1. Newman S. P.,
    2. Steed K. P.,
    3. Hooper G.,
    4. Jones J. I.,
    5. Upchurch F. C.

    Improved targeting of beclomethasone dipropionate (250 micrograms metered dose inhaler) to the lungs of asthmatics with the Spacehaler. Respir. Med. 1999, 93 (6), 424–431.

    OpenUrlPubMed
25. 25.
    1. Leach C. L.,
    2. Davidson P. J.,
    3. Boudreau R. J.

    Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC beclomethasone. Eur. Respir. J. 1998, 12 (6), 1346–1353.

    OpenUrlAbstract
26. 26.
    1. Dickinson P. A.,
    2. Howells S. W.,
    3. Kellaway I. W.

    Novel nanoparticles for pulmonary drug administration. J. Drug Target 2001, 9 (4), 295–302.

    OpenUrlPubMedWeb of Science
27. 27.
    1. Kraft W. K.,
    2. Steiger B.,
    3. Beussink D.,
    4. Quiring J. N.,
    5. Fitzgerald N.,
    6. Greenberg H. E.,
    7. Waldman S. A.

    The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin. Pharmacol. 2004, 44 (1), 67–72.

    OpenUrlCrossRefPubMed
28. 28.
    1. Videira M. A.,
    2. Botelho M. F.,
    3. Santos A. C.,
    4. Gouveia L. F.,
    5. Pedrosos De Lima J. J,
    6. Almeida A. J.

    Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target 2002, 10 (8), 607–613.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.
    1. Lamm M. E.

    Interactions of antigens and antibodies at mucosal surfaces. Ann. Rev. Microbiol. 1997, 51, 311–340.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.
    1. Vila A.,
    2. Sanchez A.,
    3. Janes K.,
    4. Behrens I.,
    5. Kissel T.,
    6. Vila J. L.,
    7. Alonso M. J.

    Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57 (1), 123–131.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.
    1. Vila A.,
    2. Sanchez A.,
    3. Evora C.,
    4. Soriano I.,
    5. Vila J. J.,
    6. Alonso M. J.

    PEG-PLA nanoparticles as carriers for nasal vaccine delivery. Aerosol Med. 2004, 17 (2), 174–185.

    OpenUrl
32. 32.
    1. Jung T.,
    2. Kamm W.,
    3. Breitenbach A.,
    4. Hungerer K. D.,
    5. Hundt E.,
    6. Kissel T.

    Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graftpoly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 2001, 18 (3), 352–360.

    OpenUrlPubMed
33. 33.
    1. Pinto-Alphandary P.,
    2. Andremont A.,
    3. Couvreur P.

    Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrobial Agents 2000, 13 (3), 155–168.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.
    1. Kumar M.,
    2. Kong X.,
    3. Behera A. K.,
    4. Hellermann G. R.,
    5. Lockey R. F.,
    6. Mohapatra S. S.

    Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy for allergic asthma. Gen. Vacc. Ther. 2003, 1 (1), 3–11.

    OpenUrl
35. 35.↵
    1. Zeng A.,
    2. Martin C. G.,
    3. Marriott C.

    The controlled delivery of drugs to the lung. Int. J. Pharm. 1995, 124 (2), 149–164.

    OpenUrl
36. 36.↵
    1. Suarez S.,
    2. Gonzalez-Rothi R. J.,
    3. Schreier H.,
    4. Hochhaus G.

    Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm. Res. 1998, 15 (3), 461–465.

    OpenUrlPubMed
37. 37.↵
    1. Fielding R.,
    2. Ahra R. M.

    Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. 1992, 9 (2), 220–223.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Canonico A. E.,
    2. Plitman J. D.,
    3. Conary J. T.,
    4. Meyrick B. O.,
    5. Brigham K. L.

    No lung toxicity after repeated aerosol or intravenous delivery of plasmidcationic liposome complexes. J. Appl. Physiol. 1994, 77 (1), 415–419.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Eastman S. J.,
    2. Tousignant J. D.,
    3. Lukason M. J.,
    4. Murray H.,
    5. Siegel C. S.,
    6. Constantino P.,
    7. Harris D. J.,
    8. Cheng S. H.,
    9. Scheule R. K.

    Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complex. Hum. Gene Ther. 1997, 8 (3), 313–322.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. McLachlan G.,
    2. Davidson D. J.,
    3. Stevenson B. J.,
    4. Dickinson P.,
    5. Davidson-Smith H.,
    6. Dorin J. R.,
    7. Porteous D. J.

    Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther. 1995, 2 (9), 614–622.

    OpenUrlPubMedWeb of Science
41. 41.↵
    1. McCluskie M. J.,
    2. Chu Y.,
    3. Xia J. L.,
    4. Jessee J.,
    5. Gebyehu G.,
    6. Davis H. L.

    Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev. 1998, 8 (5), 401–414.

    OpenUrlPubMedWeb of Science
42. 42.↵
    1. Zou Y.,
    2. Zong G.,
    3. Ling Y. H.,
    4. Perez-Soler R.

    Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther. 2000, 7 (5), 683–696.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Stribling S.,
    2. Brunette E.,
    3. Liggitt D.,
    4. Gaensler K.,
    5. Debs R.

    Aerosol gene delivery in vivo. Proc. Natl. Acad. Sci. USA 1992, 89 (23), 11277–11281.

    OpenUrlAbstract/FREE Full Text
44. 44.↵
    1. Schreier H.,
    2. Mobley W. C.,
    3. Concessio N.,
    4. Hickey A. J.,
    5. Niven R. W.

    Formulation and in vitro performance of liposome powder aerosols. STP Pharma Sciences 1994, 4 (1), 38–44.

    OpenUrl
45. 45.↵
    1. Joshi M.,
    2. Misra A.

    Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. Int. J. Pharm. 2001, 223 (1–2), 15–27.

    OpenUrlPubMed
46. 46.↵
    1. Skalko-Basnet N.,
    2. Pavelic Z.,
    3. Becirevic-Lacan M.

    Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev. Ind. Pharm. 2000, 26 (12), 1279–1284.

    OpenUrlPubMed
47. 47.↵
    1. Seville P. C.,
    2. Kellaway I. W.,
    3. Birchall J. C.

    Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J. Gene Med. 2002, 4 (4), 428–437.

    OpenUrlPubMed
48. 48.↵
    1. Kim J. C.,
    2. Kim J. D.

    Preparation by spray-drying of amphotericin Bphospholipid composite particles and their anticellular activity. Drug Deliv. 2001, 8 (3), 143–147.

    OpenUrlPubMed
49. 49.
    1. Letsou G. V.,
    2. Safi H. J.,
    3. Reardon M. J.,
    4. Ergenoglu M.,
    5. Li Z.,
    6. Klonaris C. N.,
    7. Baldwin J. C.,
    8. Gilbert B. E.,
    9. Waldrep J. C.

    Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. 1999, 68 (6), 2044–2048.

    OpenUrlPubMed
50. 50.
    1. Liu F. Y.,
    2. Shao Z.,
    3. Kildsig D. O.,
    4. Mitra A. K.

    Pulmonary delivery of free and liposomal insulin. Pharm. Res. 1993, 10 (2), 228–232.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.
    1. Padmanabhan R. V.,
    2. Gudapaty R.,
    3. Liener E. E.,
    4. Schwartz B. A.,
    5. Hoidal J. R.

    Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am. Rev. Respir. Dis. 1985, 132 (1), 164–167.

    OpenUrlPubMedWeb of Science
52. 52.
    1. Khanna C.,
    2. Hasz D. E.,
    3. Klausner J. S.,
    4. Anderson P. M.

    Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin. Cancer Res. 1996, 2 (4), 721–734.

    OpenUrlAbstract
53. 53.
    1. Griffiths G. D.,
    2. Phillips G. J.,
    3. Bailey S. C.

    Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 1999, 17 (20–21), 2562–2568.

    OpenUrlCrossRefPubMedWeb of Science
54. 54.↵
    1. Colletier J. P,
    2. Chaize B.,
    3. Winterhalter M.,
    4. Fournier D.

    Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol. 2002, 2 (9), 1–8.

    OpenUrlCrossRefPubMed
55. 55.↵
    1. Galovic R. R.,
    2. Barisic K.,
    3. Pavelic Z.,
    4. Zanic G. T.,
    5. Cepelak I.,
    6. Filipovic-Grcic J.

    High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur. J. Pharm. Sci. 2002, 15 (5), 441–448.

    OpenUrlPubMed
56. 56.↵
    1. Wagner A.,
    2. Vorauer-Uhl K.,
    3. Kreismayr G.,
    4. Katinger H.

    Enhanced protein loading into liposomes by the multiple crossflow injection technique. J. Liposome Res. 2002, 12 (3), 271–283.

    OpenUrlCrossRefPubMed
57. 57.↵
    1. Mozafari M. R.,
    2. Reed C. J.,
    3. Rostron C.,
    4. Kocum C.,
    5. Piskin E.

    Formation and characterisation of non-toxic anionic liposomes for delivery of therapeutic agents to the pulmonary airways. Cell Mol. Biol. Lett. 2002, 7 (2), 243–244.

    OpenUrlPubMed
58. 58.↵
    1. Mozafari M. R.,
    2. Hasirci V.

    Mechanism of calcium ion induced multilamellar vesicle-DNA interaction. J. Microencapsul. 1998, 15 (1), 55–65.

    OpenUrlPubMed
59. 59.↵
    1. Mozafari M. R.,
    2. Zareie M. H.,
    3. Piskin E.,
    4. Hasirci V.

    Formation of supramolecular structures by negatively charged liposomes in the presence of nucleic acids and divalent cations. Drug Deliv. 1998, 5 (2), 135–141.

    OpenUrlPubMed
60. 60.↵
    1. Zareie M. H.,
    2. Mozafari M. R.,
    3. Hasirci V.,
    4. Piskin E.

    Scanning tunnelling microscopy investigation of liposome-DNA-Ca2+ complexes. J. Liposome Res. 1997, 7 (4), 491–502.

    OpenUrl
61. 61.↵
    1. Bot A. I.,
    2. Tarara T. E.,
    3. Smith D. J.,
    4. Bot S. R.,
    5. Woods C. M.,
    6. Weers J. G.

    Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. 2000, 17 (3), 275–283.

    OpenUrlCrossRefPubMedWeb of Science
62. 62.↵
    1. Hutchinson F. G.,
    2. Furr B. J.

    Biodegradable polymers for controlled release of peptides and proteins. Horiz. Biochem. Biophys. 1989, 9, 111–129.

    OpenUrlPubMed
63. 63.↵
    1. Ehrhardt C.,
    2. Fiegel J.,
    3. Fuchs S.,
    4. Abu-Dahab R.,
    5. Schaefer U. F.,
    6. Hanes J.,
    7. Lehr C. M.

    Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J. Aerosol Med. 2002, 15 (2), 131–139.

    OpenUrlCrossRefPubMed
64. 64.
    1. Evora C.,
    2. Soriano I.,
    3. Rogers R. A.,
    4. Shakesheff K. N.,
    5. Hanes J.,
    6. Langer R.

    Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Controlled Release 1998, 51 (2–3), 143–152.

    OpenUrlCrossRefPubMedWeb of Science
65. 65.
    1. Morimoto K.,
    2. Katsumata H.,
    3. Yabuta T.,
    4. Iwanaga K.,
    5. Kakemi M.,
    6. Tabata Y.,
    7. Ikada Y.

    Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol. 2000, 52 (6), 611–617.

    OpenUrlPubMed
66. 66.
    1. Dalby R.,
    2. Bryon P. R.,
    3. Peart J.,
    4. Farr S. J.

    1. Scott T.,
    2. Sullivan A.,
    3. Proos R.

    Novel Technology for Fabrication of Therapeutic Microspheres for Pulmonary Delivery. In Respiratory Drug Delivery VIII; Dalby R., Bryon P. R., Peart J., Farr S. J. Eds.; Davis Horwood International Publishing: Raleigh, NC, 2002; pp 435–437.
67. 67.
    1. Dhiman N.,
    2. Khuller G. K.

    Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol. Med. Microbiol. 1998, 21 (1), 19–28.

    OpenUrlPubMed
68. 68.
    1. Kawashima Y.,
    2. Yamamoto H.,
    3. Takeuchi H.,
    4. Fujioka S.,
    5. Hino T.

    Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Controlled Release 1999, 62 (1–2), 279–287.

    OpenUrlCrossRefPubMedWeb of Science
69. 69.
    1. Edwards D. A.,
    2. Hanes J.,
    3. Caponetti G.,
    4. Hrkach J.,
    5. Ben-Jebria A.,
    6. Eskew M. L.,
    7. Mintzes J.,
    8. Deaver D.,
    9. Lotan N.,
    10. Langer R.

    Large porous particles for pulmonary drug delivery. Science 1997, 276 (5320), 1868–1871.

    OpenUrlAbstract/FREE Full Text
70. 70.
    1. Dalby R.,
    2. Byron P. R.,
    3. Peart J.,
    4. Farr S. J.

    1. Brown L. R.,
    2. Rashba-Step J.,
    3. Scott T.,
    4. Yuanxi Q.,
    5. Rulon P. W.,
    6. McGeehan J.,
    7. Hogeland K.,
    8. Fortier R.,
    9. Sullivan A.,
    10. Proos R.,
    11. Peters L.

    Pulmonary Delivery of Novel Insulin Microspheres. In Respiratory Drug Delivery XIII; Dalby R., Byron P. R., Peart J., Farr S. J. Eds.; Davis Horwood International Publishing: Raleigh, NC, 2002; pp 431–433.
71. 71.
    1. Surendrakumar K.,
    2. Martyn G. P.,
    3. Hodgers E. C. M.,
    4. Jansen M.,
    5. Blair J. A.

    Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Controlled Release 2003, 91 (3), 385–394.

    OpenUrlCrossRefPubMed
72. 72.
    1. Pfutzner A.,
    2. Mann A. E.,
    3. Steiner S. S.

    Technosphere/insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther. 2002, 4 (5), 589–594.

    OpenUrlCrossRefPubMed
73. 73.
    1. Steiner S.,
    2. Pfutzner S.,
    3. Wilson B. R.,
    4. Harzer O.,
    5. Heinemann L.,
    6. Rave K.

    Technosphere/insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol. Diabetes 2002, 110, 17–21.

    OpenUrlCrossRefPubMedWeb of Science
74. 74.
    1. Garcia-Contreras L.,
    2. Morcol T.,
    3. Bell S. J.,
    4. Hickey A. J.

    Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSciTech 2003, 5 (2), 10–20.

    OpenUrl
75. 75.
    1. Dalby R.,
    2. Byron P. R.,
    3. Peart J.,
    4. Farr S. J.

    1. Bhat M.

    Development of a Novel Spray-Drying Technique To Produce Particles for Aerosol Delivery. In Respiratory Drug Delivery XIII; Dalby R., Byron P. R., Peart J., Farr S. J. Eds.; Davis Horwood International Publishing: Raleigh, NC, 2002; pp 427–429.
76. 76.
    1. Dalby R.,
    2. Byron P. R.,
    3. Peart J.,
    4. Farr S. J.

    1. Blair J.,
    2. Coghlan D.,
    3. Langner E.,
    4. Jansen M.,
    5. Askey-Sarvar A.

    Sustained Delivery of Insulin via the Lung Using Solidose Technology. In Respiratory Drug Delivery VIII; Dalby R., Byron P. R., Peart J., Farr S. J. Eds.; Davis Horwood International Publishing: Raleigh, NC, 2002; pp 411–414.
77. 77.↵
    1. Cheng Y. S.,
    2. Yazzie D.,
    3. Gao J.,
    4. Muggli D.,
    5. Etter J.,
    6. Rosenthal G. J.

    Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. J. Aerosol Med. 2003, 16 (1), 65–73.

    OpenUrlPubMed
78. 78.↵
    1. Fiegel J.,
    2. Ehrhardt C.,
    3. Schaefer U. F.,
    4. Lehr C. M.,
    5. Hanes J.

    Large porous particle impingement on lung epithelial cell monolayers—toward improved particle characterization in the lung. Pharm. Res. 2003, 20 (5), 788–796.

    OpenUrlCrossRefPubMed
79. 79.↵
    1. Bittner B.,
    2. Kissel T.

    Ultrasonic atomization for spray drying: a versatile technique for the preparation of protein loaded biodegradable microspheres. J. Microencapsul. 1999, 16 (3), 325–341.

    OpenUrlCrossRefPubMedWeb of Science
80. 80.↵
    1. Dalby R.,
    2. Byron P. R.,
    3. Peart J.,
    4. Farr S. J.

    1. Plowman S.,
    2. Langner E.,
    3. Blair J.

    Elucidation of Insulin Release Mechanism from OED Microparticles Using ATR-FTIR. In Respiratory Drug Delivery VIII; Dalby R., Byron P. R., Peart J., Farr S. J. Eds.; Davis Horwood International Publishing: Raleigh, NC, 2002; pp 423–426.
81. 81.↵
    1. Takeuchi H.,
    2. Yamamoto H.,
    3. Kawashima Y.

    Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 2001, 47 (1), 39–54.

    OpenUrlCrossRefPubMed
82. 82.
    1. Bruck A.,
    2. Abu-Dahab R.,
    3. Borchard G.,
    4. Schafer U. F.,
    5. Lehr C. M.

    Lectin functionalized liposomes for pulmonary drug delivery: interaction with human alveolar epithelial cells. J. Drug Target. 2001, 9 (4), 241–251.

    OpenUrlPubMedWeb of Science
83. 83.
    1. Abu-Dahab R.,
    2. Schafer U. F.,
    3. Lehr C. M.

    Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur. J Pharm. Sci. 2001, 14 (1), 37–46.

    OpenUrlCrossRefPubMedWeb of Science
84. 84.
    1. Yanagihara K.,
    2. Cheng P. W.

    Lectin enhancement of the lipofection efficiency in human lung carcinoma cells. Biochim. Biophys. Acta 1999, 1472 (1–2), 25–33.

    OpenUrlPubMed
85. 85.
    1. Fajac I,
    2. Briand P.,
    3. Monsigny M.,
    4. Midoux P.

    Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Hum. Gene Ther. 1999, 10 (3), 395–406.

    OpenUrlCrossRefPubMed
86. 86.
    1. Fajac I.,
    2. Thévenot G.,
    3. Bédouet L.,
    4. Danel C.,
    5. Riquet M.,
    6. Merten M.,
    7. Figarella C.,
    8. Ava-Santucci J. D.,
    9. Monsigny M.,
    10. Briand P.

    Uptake of plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated airway epithelial cells. J. Gene Med. 2003, 5 (1), 38–48.

    OpenUrlPubMed
87. 87.
    1. Allo J. C.,
    2. Midoux P.,
    3. Merten M.,
    4. Souil E.,
    5. Lipecka J.,
    6. Figarella C.,
    7. Monsigny M.,
    8. Briand P.,
    9. Fajac I.

    Efficient gene transfer into human normal and cystic fibrosis tracheal gland serous cells with synthetic vectors. Am. J. Respir. Cell Mol. Biol. 2000, 22 (2), 166–175.

    OpenUrlPubMed
88. 88.
    1. Fajac I.,
    2. Grosse S.,
    3. Briand P.,
    4. Monsigny M.

    Targeting of cell receptors and gene transfer efficiency: a balancing act. Gene Ther. 2002, 9 (11), 740–742.

    OpenUrlPubMed
89. 89.
    1. Robbins J. C.,
    2. Lam M. H.,
    3. Tripp C. S.,
    4. Bugianesi R. L.,
    5. Ponpipom M. M.,
    6. Shen T. Y.

    Synthetic glycopeptide substrates for receptor-mediated endocytosis by macrophages. Proc. Natl Acad. Sci. USA 1981, 78 (12), 7294–7298.

    OpenUrlAbstract/FREE Full Text
90. 90.
    1. Derrien D.,
    2. Midoux P.,
    3. Petit C.,
    4. Nègre E.,
    5. Mayer R.,
    6. Monsigny M.,
    7. Roche A. C.

    Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj. J. 1989, 6 (2), 241–255.

    OpenUrlCrossRefPubMed
91. 91.
    1. Liang W. W.,
    2. Shi X.,
    3. Deshpande D.,
    4. Malanga C. J.,
    5. Rojanasakul C. J.

    Oligonucleotide targeting to alveolar macrophages by mannose receptormediated endocytosis. Biochim. Biophys. Acta 1996, 1279 (2), 227–234.

    OpenUrlPubMed
92. 92.
    1. Briscoe P.,
    2. Caniggia I.,
    3. Graves A.,
    4. Benson B.,
    5. Huang L.,
    6. Tanswell A. K.,
    7. Freeman B. A.

    Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am. J. Physiol. 1995, 268, L374–L380.

    OpenUrlPubMed
93. 93.
    1. Ross G. F.,
    2. Morris R. E.,
    3. Ciraolo G.,
    4. Huelsman K.,
    5. Bruno K.,
    6. Whitsett J. A.,
    7. Baatz J. E.,
    8. Korfhagen T. R.

    Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture. Hum. Gene Ther. 1995, 6 (1), 31–40.

    OpenUrlCrossRefPubMed
94. 94.
    1. Walther F. J.,
    2. David-Cu R.,
    3. Supnet M. C.,
    4. Longo M. L,
    5. Fan B. R.,
    6. Bruni R.

    Uptake of antioxidants in surfactant liposomes by cultured alveolar type II cells is enhanced by SP-A. Am. J. Physiol. 1993, 265 (4 Pt 1), L330–L339.

    OpenUrlPubMed
95. 95.
    1. Frederiksen K. S.,
    2. Abrahamsen N.,
    3. Cristiano R. J.,
    4. Damstrup L.,
    5. Poulsen H. W.

    Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther. 2000, 7 (2), 262–268.

    OpenUrlCrossRefPubMed
96. 96.
    1. Cristiano R. J.,
    2. Roth J. A.

    Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther. 1996, 3 (1), 4–10.

    OpenUrlPubMedWeb of Science
97. 97.
    1. Yanagihara K.,
    2. Cheng H.,
    3. Cheng P. W.

    Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells. Cancer Gene Ther. 2000, 7 (1), 59–65.

    OpenUrlCrossRefPubMed
98. 98.
    1. Gladysheva I. P.,
    2. Moroz N. A.,
    3. Karmakova T. A.,
    4. Nemtsova E. R.,
    5. Yakubovskaya R. I.,
    6. Larionova N. I.

    Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents. J. Drug Target. 2001, 9 (5), 303–316.

    OpenUrlPubMed
99. 99.
    1. Mastrobattista E.,
    2. Storm G.,
    3. van Bloois L.,
    4. Reszka R.,
    5. Bloemen R. P. G.,
    6. Crommelin D. J. A.,
    7. Henricks P. J. A.

    Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim. Biophys. Acta 1999, 1419 (2), 353–363.

    OpenUrlPubMed
100. 100.
     1. Scott E. S.,
     2. Wiseman J. W.,
     3. Evans M. J.,
     4. Colledge W. H.

     Enhanced gene delivery to human airway epithelial cells using an integrin-targeting lipoplex. J. Gene Med. 2001, 3 (2), 125–134.

     OpenUrlCrossRefPubMedWeb of Science
101. 101.
     1. Torchilin V. P.

     TAT peptide-modified liposomes for intracellular delivery of drugs and DNA. Cell Mol. Biol. Lett. 2002, 7 (2), 265–267.

     OpenUrlPubMed
102. 102.
     1. Wu M.,
     2. Pasula R.,
     3. Smith P. A.,
     4. Martin W. J.

     Mapping alveolar binding sites in vivo using phage peptide libraries. Gene Ther. 2003, 10 (17), 1429–1436.

     OpenUrlCrossRefPubMed
103. 103.
     1. Kreda S. M.,
     2. Pickles R. J.,
     3. Lazarowski E. R.,
     4. Boucher R. C.

     G-protein coupled receptors as targets for gene transfer vectors using natural smallmolecule ligands. Nat. Biotechnol. 2000, 18 (6), 635–640.

     OpenUrlCrossRefPubMedWeb of Science
104. 104.
     1. Goren D.,
     2. Horowitz A. T.,
     3. Tzemach D.,
     4. Tarshish M.,
     5. Zalipsky S.,
     6. Gabizon A.

     Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 2000, 6 (5), 1949–1957.

     OpenUrlAbstract/FREE Full Text
105. 105.
     1. Reddy. J. A.,
     2. Low P. S.

     Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15 (6), 587–627.

     OpenUrlPubMedWeb of Science
106. 106.
     1. Deshpande D.,
     2. Toledo-Velasquez D.,
     3. Wang L. Y.,
     4. Malanga C. J.,
     5. Ma J. K.,
     6. Rojanasakul Y.

     Receptor-mediated peptide delivery in pulmonary epithelial monolayers. Pharm. Res. 1994, 11 (8), 1121–1126.

     OpenUrlCrossRefPubMedWeb of Science
107. 107.
     1. Rudolph C.,
     2. Schillinger U.,
     3. Plank C.,
     4. Gessner A.,
     5. Nicklaus P.,
     6. Müller R.,
     7. Rosenecker J.

     Nonviral gene delivery to the lung with copolymer-protected and transferrin-modified polyethylenimine. Biochim. Biophys. Acta 2002, 1573 (1), 75–83.

     OpenUrlPubMed
108. 108.↵
     1. Torchilin V. P.

     1. Unger E. C.,
     2. Zutshi R.,
     3. Matsunaga T. O.,
     4. Ramaswami R.

     Lipid-Coated Submicron-Sized Particles as Drug Carriers. In Nanoparticulates as Drug Carriers; Torchilin V. P. Ed.; Imperial College Press: London, 2006; pp 248–249.
109. 109.↵
     1. Smola M.,
     2. Vandamme T.,
     3. Sokolowski A.

     Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. International Journal of Nanomedicine 2008, 3 (1), 1–19.

     OpenUrlPubMed
110. 110.↵
     1. Cindy H.

     Inhalation: going beyond asthma! Drug Del. Technol. 2010, 10 (3), 35–42.

     OpenUrl
111. 111.↵
     1. Pilcer G.,
     2. Vanderbist F.,
     3. Amighi K.

     Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int. J. Pharm. 2009, 365 (1–2), 162–169.

     OpenUrlPubMed
112. 112.↵
     1. Shaikh S.,
     2. Nazim S.,
     3. Shaikh A.,
     4. Khan T.

     Recent trends in applications of pulmonary drug delivery: a review. Int. J. of Pharma Res. & Development. 2011, 2 (12), 171–180.

     OpenUrl
113. 113.↵
     1. Muttil P.,
     2. Wang C.,
     3. Hickey A.

     Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 2009, 26 (11), 2401–2416.

     OpenUrlCrossRefPubMedWeb of Science